Board of Directors
News & Media
Investor and Media Contact
Systemic Lupus Erythematosus
Investor Update and Notice of Investor Briefing
Annual General Meeting Notice of Meeting and Explanatory Memorandum
Corporate Governance Statement and Appendix 4G
Invion is a life sciences company focussed on the development of treatments for major opportunities in inflammatory diseases. Invion is an ASX listed company (ASX:IVX), with operations in Brisbane, Australia and Delaware, USA.
Invion has entered into an exclusive commercialisation and distribution agreement to NGPDT technologies for the treatment of cancers, as well as a global R&D Agreement to conduct clinical trials initially targeting prostate cancer.
Invion Limited – Targeting Inflammation